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Abstract
Introduction: Reimbursement decisions on orphan drugs carry significant uncer-
tainty, and as the amount increases, so does the risk of making a wrong decision, 
where harms outweigh benefits. Consequently, patients often face limited access to 
orphan drugs. Managed access programmes (MAPs) are a mechanism for managing 
risk while enabling access to potentially beneficial drugs. Patients and their caregiv-
ers have expressed support for these programmes and see patient input as critical to 
successful implementation. However, they have yet to be systematically involved in 
their design.
Objective: The aim of this study was to co- design with patients and caregivers a tool 
for the development of managed access programmes.
Methods: Building upon established relationships with the Canadian Organization 
for Rare Disorders, the project team collaborated with patients and caregivers using 
the principles of participatory action research. Data were collected at two work-
shops and analysed using a thematic network approach.
Results: Patients and caregivers co- designed a checklist comprised of six aspects of 
an ideal MAP relating to accountability (programme goals); governance (MAP- specific 
committee oversight, patient input, international collaboration); and evidence collec-
tion (outcome measures and continuation criteria, on- going monitoring and regis-
tries). They recognized that health- care resources are finite and considered disease 
or drug eligibility criteria for deciding when to use a MAP (eg drugs treating diseases 
for which there are no other legitimate alternatives).
Conclusions: A patient and caregiver- designed checklist was created, which empha-
sized patient involvement and transparency. Further research is needed to examine 
the feasibility of this checklist and roles for other stakeholders.
K E Y W O R D S
managed access programmes, orphan drugs, patient input, patient involvement, rare diseases
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1  | INTRODUC TION
Reimbursement decisions on orphan drugs (ie medicines for treating 
rare diseases affecting less than 5 in 10 000 people in the European 
Union1) carry significant uncertainty.2,3 Uncertainty typically arises 
from a lack of high- quality information on (i) clinical benefit, (ii) value 
for money, (iii) potential adoption/diffusion and (iv) affordability.4,5 
The natural histories of many rare diseases, which tend to be life- 
threatening or severely debilitating, remain poorly understood, and 
high- quality randomized clinical trials are often difficult to conduct 
because of small patient populations and limited validated outcome 
measures.5,6
As uncertainty increases, so does the risk of making a “wrong 
decision.” Patients may be harmed and resources may be wasted 
when a treatment provided turns out to be ineffective or unsafe or 
when a treatment not provided turns out to be effective.4 Therefore, 
to manage risk while enabling access to potentially beneficial drugs, 
innovative ways of introducing these drugs have been developed,7-9 
one of which may be referred to as managed access programmes 
(MAPs).4 MAPs provide patients with a drug while information 
needed to address uncertainties is collected to inform a definitive 
coverage decision. As an outcome- based arrangement, they resem-
ble complex patient access schemes offered through NHS England.10 
In Canada, patients, caregivers and patient organizations have ex-
pressed support for MAPs. Further, they perceive their input to be 
critical to successful implementation, should such a policy option be 
adopted. However, they have yet to be systematically involved in 
their design.4,11
2  | OBJEC TIVE
The aim of this study was to co- design with patients and caregivers a 
tool for the development of managed access programmes.
3  | METHODS
A participatory action research (PAR) approach was used. PAR 
requires the active involvement of researchers and participants 
in co- constructing knowledge; promoting self- and critical 
awareness (which leads to individual, collective and/or social 
change); and building alliances for effective planning, imple-
mentation and dissemination of the research.12 In Canada, the 
Canadian Organization for Rare Disorders (CORD) represents 
the rare diseases community. It is comprised of more than 80 
patient organizations and is recognized as the national voice 
of this community, advocating for appropriate access to care. 
In this study, we built on established relationships between 
CORD and members of the study team. At the same time, re-
cent research from our group had demonstrated that there 
was strong interest in the CORD community in a possible role 
for patients and families in developing innovative approaches, 
such as MAPs, to improve coverage for orphan and ultra- orphan 
drugs.13 
Two workshops were held using the methods described below.
3.1 | Study population
All patients and caregivers at two CORD Regional Forums were in-
vited to participate in the workshops, which were part of the main 
Forum programme (ie no other sessions were scheduled at the same 
time). The Forums focused on strategies for sustainable access to 
therapies and explored personalized approaches to drug access. 
Presentations were made on assessing therapies for real- world use, 
strategies for responsible use and different pathways for access, 
including MAPs. Prior to the Forums, participants had participated 
in two CORD conferences focused on improving access to thera-
pies for rare diseases and efforts to accomplish this in other coun-
tries. They also included presentations on the challenges faced by 
decision- makers in Canada and discussions around the feasibility of 
applying international experience to the Canadian context. CORD 
travel grants were provided to patients and families for the confer-
ences and Forums, minimizing financial barriers to attendance.
3.2 | Data collection
Workshops built upon findings from research previously undertaken 
in collaboration with CORD (deliberative discussions with multiple 
stakeholders and then patients and caregivers, followed by webi-
nars and priority- setting exercises with patients and families) (see 
Figure S1 in Appendix A for the diagram of research progression). 
Questions focused on the 4 main types of uncertainty that decision- 
makers face (listed in the Introduction) and sought to elicit infor-
mation from participants on additional sources of uncertainty and 
aspects of MAPs important to them (see Table S1 in Appendix A for 
the list of questions). Two experienced researchers facilitated both 
workshops, which began with a presentation on MAPs and examples 
of their use. Both workshops were audio- recorded and transcribed. 
No training was provided prior to the workshop, but all of the partici-
pants had attended the Forum and CORD conferences.
3.3 | Data analysis and interpretation
Transcripts were analysed using a thematic network approach,14 a 
tool for organizing the different levels of themes that emerge in a 
thematic analysis of qualitative data. Transcripts were first coded in-
ductively using open coding methods.15 Codes were then clustered 
into “basic themes,” describing the premise of the coded data (eg 
no legitimate drug alternatives).14 Basic themes focusing on similar 
issues were further grouped into “organizing themes” (eg drug pri-
orities for MAPs).14 Finally, organizing themes were grouped into 
“global themes,” capturing what they meant as a whole (eg best prac-
tices for an ideal managed access programme).14 Constant compara-
tive analysis was used to organize codes into themes,15 which were 
subsequently mapped onto an uncertainties matrix, reflecting their 
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link to a specific type of uncertainty. Finally, by considering how the 
themes could be operationalized in the implementation of a MAP, an 
“ideal” MAP checklist was created similar to commonly used critical 
appraisal tools.
The checklist was reviewed by workshop participants, minimiz-
ing opportunities for bias in the interpretation of data. It was then 
presented to a broader group of stakeholders who comprise mem-
bers of the research and advisory teams of Promoting Rare- Disease 
Innovation through Sustainable Mechanisms (PRISM; a Canadian re-
search network through which this project was funded) for further 
feedback. These teams include clinicians, regulators, provincial drug 
plan decision- makers and industry representatives. Based on com-
ments received, a final version of the checklist was prepared.
4  | RESULTS
All patients and caregivers who attended the Regional Forum par-
ticipated in the workshop. They represented a range of disease 
types (eg cancer, non- cancerous tumour disorders, blood disorders, 
metabolic disorders, connective tissue disease, endocrine disorders, 
lung disorders and epileptic encephalopathies) and differing levels 
of experience within their rare disease communities. Nine patients 
and three caregivers (10 females; 2 males) participated in the first 
workshop, and five patients and three caregivers (7 females; 1 male) 
participated in the second.
Through the workshops, four global themes reflecting “notions” 
were identified. A notion is an individual’s impression of something 
known, experienced or imagined16 The notions related to patients’ 
and caregivers’ experiences living with a rare disease and access-
ing appropriate therapies (eg orphan drugs). Collectively these ap-
peared to guide their views on what they considered a MAP that 
they felt would provide the necessary, but missing information on 
a new therapy. In addition to these notions, patients and caregivers 
also identified specific aspects of an ideal MAP. Overarching the four 
notions and the aspects of an ideal MAP was “sentiments,” capturing 
why patients valued MAPs and wanted to be involved in their design. 
Further details on each notion, including examples from the tran-
scripts, can be found in Appendix A (Tables S2 and S3).
4.1 | The four notions
The four notions are organized below in order of relevant stage in 
the life cycle of an orphan drug. Refer to Appendix A to see the the-
matic networks behind each notion (Figures S2-S5) and for further 
details on the life cycle (Figure S6).
4.1.1 | All stakeholders have roles and 
responsibilities in the orphan drug life cycle
Patients and caregivers believed that all stakeholders “[have] a role 
and… a responsibility” (Patient 5, Workshop 1 or P5, W1) within the 
orphan drug life cycle (“I’m sorry, it’s like if you don’t go to vote, you 
can’t complain!” – Caregiver 1, W1 or C1, W1), and saw themselves 
as experts in the “lived” experience. At the same time, they de-
scribed challenges in this role, which related to the physician–pa-
tient relationship. Patients and caregivers often face pushback from 
physicians who are “not open… [And] don’t always listen” (P5, W2) to 
information patients/caregivers have gathered through their own 
research and experiences.
In general, patient organizations were viewed as trusted repre-
sentatives of and important information conduits for the disease 
community. As such, they are well positioned to identify and inform 
patients about opportunities to be involved in the life cycle (eg to 
provide input into coverage decision making). When asked whether 
there is a role for patient organizations in educating and managing 
expectations of patients and caregivers around new therapies for 
which there may be limited clinical evidence, patients and caregiv-
ers responded “absolutely.” They also felt that those who formally or 
informally contribute to decision making within the life cycle should 
share their knowledge and insights with the rest of the disease 
community.
With respect to the role of physicians, patients and caregivers 
felt that physicians should be responsible for ensuring their patients 
are aware of all treatment options, regardless of the cost. Several 
expressed frustrations with physicians who “didn’t read the literature” 
(P2, W2) and struggled to effectively provide care due to unfamiliar-
ity with the rare disease.
4.1.2 | Research on rare diseases and orphan drugs 
is challenging
Patients and caregivers reiterated the challenges involved in con-
ducting research on rare diseases and orphan drugs, the most sig-
nificant of which remains the poorly understood natural histories of 
rare diseases (“Well finally, at least we know I’m not the only one…” – 
P5, W2) and its impact on the discovery of effective therapies. They 
emphasized the importance of on- going collection of natural history 
and clinical outcomes data. They recognized that while registries 
may play a role, they require significant resources to implement and 
maintain. “Many drugs can’t support that type of registry” and there are 
“the physicians as well…they don’t have time to fill out the paper work” 
(P3, W2) for on- going data collection.
Patients and caregivers also identified challenges involved in 
conducting clinical trials on orphan drugs in Canada. In their view, 
trials are “not likely to be happening in Canada” (P4, W2), which is a 
concern, as they represent an important means of obtaining early 
access to new therapies. Regardless of location, trials are limited by 
small patient sample sizes (“we didn’t have 99 patients that were going 
to enroll”— C2, W2) and a lack of validated outcome measures.
4.1.3 | Challenges around coverage decision- making 
processes affect access to orphan drugs
Patients and caregivers discussed challenges in Canadian cover-
age decision- making processes that affect their ability to access 
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orphan drugs. They appreciated that coverage decision making 
is complicated by the significant uncertainties that exist around 
the clinical benefit of orphan drugs when one is “not quite sure 
how it’s going to be used and what the outcomes will be…” (P1, W2). 
However, they questioned why such processes do not routinely 
involve specialist physicians “who know something about the dis-
ease and the drug” (C1, W2). They also acknowledged the high 
cost of orphan drugs as an added challenge for decision- makers, 
as well as desperate demands from patients and families for ac-
cess to treatments with “no data to support [them] whatsoever…” 
(P4, W1). These demands are often exacerbated by “inequality [in 
access] across Canada” (P7, W1), which they blamed on the lack of 
a national health- care system. They believed that provincial con-
trol of health- care budgets has hindered the implementation of 
nation- wide programmes, like the pan- Canadian Pharmaceutical 
Alliance (pCPA; established to conduct joint drug plan negotia-
tions for brand drugs in Canada), which could directly affect ac-
cess to orphan drugs.
There is also a lack of transparency in drug coverage decision 
making. One participant wondered: “Why don’t they have account-
ability? Why is there no transparency there?” (P6, W1). Patients and 
caregivers felt that they were purposefully kept in the dark by those 
involved who “don’t want [patients/caregivers] to know” (P1, W1).
Finally, patients and families discussed how Canada represents 
only a small share of the global drug market and is “not a friendly 
place for [pharmaceutical companies] to come to” (P8, W1). As a result, 
there is a need for the government to introduce policy mechanisms 
for bringing new drugs into Canada that provide some security for 
companies “around how long they have to recoup that money” (P8, W1).
4.1.4 | All patients are unique
Patients and caregivers explained that no single patient can repre-
sent the views of the entire disease group because all patients are 
“unique” and do “not [have] just one experience” (P1, W1) “You can’t do… 
one size fits all [with orphan drugs]” (P5, W1). Further, rare diseases 
are often heterogeneous, with symptoms, severity and response to 
treatment varying across patients who share a diagnosis (“…we’re not 
having the same bodies. We don’t have the same ways [of] metabolizing 
[drugs]” (P3, W2)). “You’re dealing with all ages, you’re dealing with dif-
ferent responses to treatment, different lifestyle… at least in our area I 
would feel very bad as a patient representative to be the only one saying 
what I think are the right outcomes” (P1, W2).
4.2 | Aspects of an ideal MAP
Additionally, patients’ and caregivers’ described the components that 
a MAP should contain. Six aspects of an ideal MAP were identified. In 
considering how to operationalize these components, a checklist was 
developed, which organized the aspects into three categories relat-
ing to accountability, governance and evidence collection (Table 1). 
An annotated version of this checklist can be found in Appendix B, 
which maps the notions onto the checklist components (Table B1).
4.2.1 | Accountability aspects
Programme goals
While patients and caregivers viewed MAPs as enabling earlier ac-
cess to potentially effective therapies, they wanted to ensure that 
this option is used appropriately or “for the right purpose” (C1, W2)—it 
must be able to address research questions aimed at determining 
the right dose of the right drug for the right patient. Individualized 
treatment protocols, which involve “trying [the drug] on each individ-
ual patient and seeing if it’s working for them or not” (C3, W2), may be 
required.
Transparency in all aspects of the MAP was emphasized. This 
includes opportunities for patient and caregiver input; as many felt 
that other stakeholders do not effectively communicate, their re-
quests for input and so the patients “don’t know when these [oppor-
tunities] happen.” It was felt that transparent MAPs would improve 
patients’ acceptance of treatment decisions by helping them “under[-
stand] the process a little more and [take] the sting out of why [they] 
can’t get medication” (P4, W1).
4.2.2 | Governance aspects
MAP- specific Committee
Patients and caregivers indicated that MAPs should be overseen 
by a MAP- specific committee with “a stipulation that there’s pa-
tient representation” (P9, W1) from three patient members who: 
1) meet a minimum level of experience within the health- care 
system, 2) have a meaningful role on the committee and 3) are 
accountable back to the organization they represent to avoid 
bias and enhance knowledge translation. To this end, they saw 
a role for patient organizations in selecting patient representa-
tives who “understand all [their] needs… [to] go on [their] behalf” 
(P3, W1).
They also agreed that committees should include a physician 
who specializes in the specific rare disease—”somebody in the med-
ical field who understands [the specific disease]” (P4, W1) and the 
patient community should select that physician. Finally, there was 
a widely held view that committee meetings should be “open to 
anybody” (P7, W1) so that all patients/caregivers have the oppor-
tunity to provide input into the programme. This is discussed in 
detail below.
Individual patient input
The importance of providing opportunities for individual pa-
tient and caregiver input in the development of a MAP was 
stressed (“the patient, in whatever format, deserves a voice” (P2, 
W1)). Further, such input must be collected through a process 
that is quick, efficient and accessible (“thinking about the peo-
ple who are at home with their disease and can’t get to meetings, 
but want to have a voice, if they have a computer and a family 
member they can sit beside them and put their answers in it”—
P3, W1). Several approaches to collecting feedback were dis-
cussed, including online surveys, written documents, videos 
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or face- to- face interviews with the committee. While most 
agreed that online surveys are an effective and efficient way 
of gathering input from as many patients as possible, some 
felt there should still be an opportunity for an individual to 
present to a committee (ie “the choice of doing it in person”—P6, 
W1).
International collaboration
Given the nature of rare diseases, patients and caregivers proposed 
collaborating with other countries on certain MAPs, using the ex-
periences of patients across multiple countries. They provided the 
example of patients who have participated in clinical trials based out 
of the United States and wondered if for MAPs there could be “a 
TABLE  1 Checklist for the characteristics of an Ideal MAP
Accountability
Programme Goals
Is the MAP appropriate for the question at hand? □	Yes □	No
Will the patients receive earlier access to the drug? □	Yes □	No
Will the programme collect the evidence needed to find the right drug for the right patient? □	Yes □	No
Will all of the processes within the programme (eg decision making) be transparent to ensure greater buy- in? □	Yes □	No
Governance
Programme- Specific Committee
Will there be a programme- specific committee established to guide the MAP? □	Yes □	No
Will there be 3 patient members on the committee? □	Yes □	No
Will the patient members meet the follow criteria:
Meet a minimum level of experience with the health- care system □	Yes □	No
Have a meaningful role on the committee? □	Yes □	No
Are accountable back to the disease community that they represent? □	Yes □	No
Will patient organizations select the patient members? □	Yes □	No
Will there be a physician committee member? □	Yes □	No
Will they be an expert in the rare disease? □	Yes □	No
Will patient organizations select the physician member? □	Yes □	No
Will the committee meetings be open to all patients and caregivers who wish to attend? □	Yes □	No
Individual Patient Input
Will individual input from a broad range of patients be collected to develop the MAP? □	Yes □	No
Will the process be quick and efficient? □	Yes □	No
Will there be a variety of ways for patients to provide input? □	Yes □	No
Will the input processes be transparent and patients well informed of the opportunity? □	Yes □	No
International Collaboration
Will there be collaboration with other countries to learn from their experiences with MAPs? □	Yes □	No
Will there be collaboration with other countries to conduct trials (if necessary)? □	Yes □	No
Will there be collaboration with experts in other countries to educate Canadian physicians on the rare disease? □	Yes □	No
Evidence Collection
On- going Monitoring and Registries
Will there be on- going monitoring with an engaged physician and good documentation (eg through EMRs)? □	Yes □	No
Will the following information be collected: □	Yes □	No
Natural history data? □	Yes □	No
Qualitative data? □	Yes □	No
Clinical outcomes? □	Yes □	No
Outcome Measures and Continuation Criteria
Will the outcome measures used be meaningful to patients and adequately capture their experiences? □	Yes □	No
Will patients provide input on meaningful outcome measures? □	Yes □	No
Will decisions to continue/discontinue therapy be made between physicians and patients without the use of set 
continuation criteria?
□	Yes □	No
Will there be follow- through on the results of the MAP? □	Yes □	No
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parallel sort of thing where the [Canadian] physician enters [data] into… 
[a] US database” (P4, W2). Also, there may be opportunities to learn 
from other countries that use MAPs and potentially “adopt one of 
[their] systems” (P1, W1).
4.2.3 | Evidence collection aspects
Outcome measures and continuation criteria
Patients and caregivers believed they should have an opportunity to 
provide input on the outcome measures selected and used as continu-
ation criteria to ensure they are meaningful. They felt that patients 
should be asked, “What do you think? What else can you tell us?” (C1, 
W2). With respect to continuation criteria, where these could not be 
determined a priori (eg for poorly understood, ultra- rare, heterogene-
ous diseases), participants felt that decisions around continuation on 
therapy should be made through a conversation between patients and 
their physicians (eg “try and up the dose”—P4, W2).
At the same time, the need to “act on the answer” (P1, W2) pro-
vided through a MAP was stressed by patients and caregivers. 
Where the treatment proves ineffective based on previously agreed 
outcomes, participants indicated it should be discontinued, with 
decision- makers enforcing follow- through.
“..so you do have to set schemes up in such a way (1) in 
hope of getting an answer and (2) that you’re going to act 
on the results in a reasonable kind of way.”  (C2, W2)
On- going monitoring and registries
Patients and caregivers felt that MAPs must have “a documentation 
process in place” (P2, W2) to support on- going monitoring with an en-
gaged physician and data collection should begin before treatment 
is started (eg natural history registries) to identify “the stages of that 
patient journey… [and] the progressions” (C1, W2) of the disease. Once 
treatment has begun, registries should collect qualitative and quan-
titative data related to the impact of the drug.
4.2.4 | Disease/drug priorities
Patients and caregivers recognized that health- care resources are finite 
and that it is infeasible to have a MAP for every drug. As such, they 
also considered possible disease or drug eligibility criteria for deciding 
when to use a MAP. They included drugs that treat “life-threatening or 
chronically debilitating conditions” (P2, W1) and those for which there are 
no other legitimate alternatives (ie when an alternative exists but is not 
an option for all patients, eg, due to intolerance). Drugs that are innova-
tive (ie offer a new mechanism of action) or high cost were also seen as 
priorities. When asked whether disease prevalence alone is a sufficient 
criterion to make a drug a priority for a MAP, patients and caregivers 
both responded “no.” While there was broad agreement from patients 
and caregivers on these criteria, some wondered “why we…are even 
thinking about excluding [drugs]” (P4, W1), arguing that the use of MAPs 
for all drugs may make the health- care system more efficient.
4.3 | The role of MAPs
In addition to the 4 notions described above, 3 overarching “senti-
ments” emerged. These captured why patients and caregivers felt 
MAPs were a reasonable solution for addressing the uncertainties 
that coverage decision- makers face. While the workshops were not 
intended to gather information on why patients and caregivers sup-
ported the use of MAPs, these sentiments were embedded through-
out their discussions around what MAPs should look like.
First, trust in other stakeholders is often lacking. Patients and 
caregivers questioned the meaningfulness of many outcome mea-
sures used in decision- making processes that they feel are opaque 
(“Maybe they don’t want us to know” – P4, W1). Some did not trust 
their physicians to know which therapies were most appropriate. 
One patient described receiving a prescription that she later “found 
out… [they] should have never… had” (P7, W2). Also, at times, they felt 
that their physician chose not to inform them of all their treatment 
options because of the costs. “Physicians [make] treatment decisions 
based on the cost of the drug” (P2, W1), not on its potential effective-
ness, assuming “[the patient] can’t afford it.”
The second “sentiment” was desperation. Patients and families 
described feeling desperate to find a treatment for their disease, 
particularly when no alternatives exist. They become willing to try 
almost anything and accept risk thresholds that are much higher 
than those accepted by their health- care providers. They “[are] emo-
tional, [and they] want to get better” (P1, W1) so if they are offered 
access to a drug in a trial or a MAP “[they’ll] sign anything” (P9, W1) 
to participate.
The third “sentiment” that emerged was hope. Patients and care-
givers were steadfast in their belief that access to orphan drugs can 
be improved. One caregiver said: “I’m not giving up for anything. And 
if my son doesn’t make it, I’ll also be fighting for the other ones” (C2, 
W1). This theme was apparent in both patients’ and caregivers’ en-
thusiasm around the workshop dedicated to the design of an ideal 
MAP and in their discussions about uncertainty and the difficulty it 
creates for decision- makers. They recognized that these uncertain-
ties are an issue, but felt there are ways they could be involved to 
help reduce them (“Let’s get [it] done…”—C2, W1), such as identifying 
meaningful outcome measures (“…it’s fairly easy to ask the [patients] 
what they would see as success”—P1, W2) and contributing to decision- 
making committees.
5  | DISCUSSION
The work described in this study contributes to the growing body 
of literature supporting the inclusion of patients in the assessment 
of new health technologies to inform reimbursement decisions. To 
date, much of the attention has been focused on the development of 
generic guidance documents for patient involvement in HTA, such as 
those developed by the European Patients Academy (EUPATI).17,18 
Several of the items on the MAP checklist are consistent with these 
documents. For example, the EUPATI calls for the nomination 
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of patient and clinical experts by patient organizations to serve 
on HTA committees. They are also consistent with The European 
Organization for Rare Diseases’ Charter that provides principles for 
collaboration between sponsors and patient organizations.19
The MAPs checklist is an example of a tool co- designed by pa-
tients and caregivers to not only improve access to high- cost drugs 
for rare diseases, but also generate the kind of evidence needed 
to inform appropriate reimbursement (ie right drug for the right 
patient at the right time). To our knowledge, no other such tool 
exists. However, some jurisdictions, such as England and Wales, 
have already implemented MAP- like schemes [ie patient access 
schemes (PAS)]. While PAS proposals from pharmaceutical com-
panies are not co- designed by patients or caregivers, their input 
is sought during the review process managed by the National 
Institute for Health and Clinical Excellence (NICE).10 Those that 
take the form of a “complex scheme,” where pricing and reim-
bursement is outcome- based, share many of the elements pre-
sented in the MAPs checklist.
Additionally, a checklist for evaluating access with evidence de-
velopment (AED) schemes, which serve a similar purpose to MAPs, 
has been published.20 Specifically, AEDs provide interim coverage to 
patients through participation in a study designed to generate evi-
dence needed to make a definitive coverage decision. The elements 
are broadly similar to those of the MAPs checklist.
While much of this work focussed on what an ideal MAP 
should look like, general discussions around the current context 
of orphan drug access, the challenges that patients and caregiv-
ers face and, ultimately, why MAPs was viewed as an appropri-
ate solution also took place. The three sentiments identified from 
these discussions (trust, hope and desperation) have been docu-
mented in published literature. One study found that patients with 
lower levels of trust in their physician were more likely to want an 
autonomous role in treatment decision making.21 Another study 
which involved a qualitative analysis of cancer patients’ conver-
sations demonstrated that hope often served as a justification for 
action.22 Finally, a recent ethics paper argued that it is a combi-
nation of desperation and hope that motivates patients with un-
treatable diseases to drastic measures to find potentially effective 
therapies.23
It was also recognized that MAPs will not address all of the is-
sues that patients and families face with respect to managing rare 
diseases (eg the exclusion of patients and specialists with relevant 
expertise from committees reviewing submissions for drug cov-
erage or disparities in access to coverage across Canadian prov-
inces and territories). Studies on the reasonableness of patients 
and their willingness to accept limits have been documented in 
other studies.24,25
5.1 | Limitations
Both workshops were held at national events hosted by CORD, and 
it is possible that the individuals who chose to participate in these 
events were not representative of the rare disease population in 
Canada. However, CORD is comprised of over 80 different rare 
disease patient organizations and covers travel expenses for pa-
tients and caregivers to attend their events, reducing the likeli-
hood of bias.
6  | CONCLUSION
The MAP checklist co- designed by patients and caregivers offers a 
tool for informing the development and evaluation of such policy 
options, which aim to improve access to drugs where there is a high 
degree of uncertainty in the available evidence. Future research is 
needed to examine the feasibility of this checklist and roles for other 
stakeholders.
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